Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lisocabtagene maraleucel + venetoclax
- Development stage
- Phase 2
- Lead developer
- Bristol Myers Squibb
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Lisocabtagene maraleucel is a CD19-directed, genetically modified autologous CAR-T cell therapy. It involves collecting a patient's T cells, engineering them to express a chimeric antigen receptor (CAR) targeting the CD19 antigen on B cells, and infusing them back into the patient to attack and kill malignant B cells. Venetoclax is an oral small molecule inhibitor of B-cell lymphoma 2 (BCL2), a protein that helps cancer cells survive by inhibiting apoptosis. The combination of these two drugs is being investigated for relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), particularly in patients who have failed prior therapies including BTK inhibitors and venetoclax monotherapy[5][8]. Lisocabtagene maraleucel was developed by Juno Therapeutics/Bristol Myers Squibb; venetoclax was developed by AbbVie/Genentech.
- Other names
- lisocabtagene maraleucel + venetoclax
02
Targets
BCL-2 (BCL-2 family)CD19 (B lymphocyte antigen CD19)
Beyond the preview
Go deeper on lisocabtagene maraleucel + venetoclax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lisocabtagene maraleucel + venetoclax.